THERAPY SELECTION FOR PSORIASIS AND PSORIATIC ARTHRITIS

The present invention provides methods for selecting an individual with psoriasis (Ps) or psoriatic arthritis (PsA) who should receive or who is likely to respond to a treatment with an anti-tumor necrosis factor alpha (anti-TNFα) therapy. In addition, provided herein are methods for selecting an individual with Ps or PsA who should receive or who is likely to respond to a therapy that is not an anti-TNFα therapy, e.g., a non-anti-TNFα therapy for the treatment of Ps or PsA. Specifically, the methods of the present invention relate to detecting the presence of distinct alleles of the PDE3A-SLCO1C1 locus which are associated with a clinical response to an anti-TNFα therapy or a non-anti-TNF therapy in patients with Ps or PsA.